Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1.
Oseltamivir was administered at 1.0 mg/kg b.i.d. to 13 neonates exposed to influenza H1N1. No influenza, neurologic, or laboratory adverse effects occurred. The mean Cmax values for oseltamivir and oseltamivir carboxylate were found to be lower than those reported for children 1 to 5 years old, whereas Tmax values were similar to children 1 to 5 years old. Age and gender were found to significantly affect oseltamivir clearance.
Department for Interventions in Health-Care Facilities, Hellenic Centre for Diseases Control and Prevention, Athens, Greece. helen-maltezou@ath.forthnet.gr
Helena C
HC
Maltezou
Nikolaos
N
Drakoulis
Tania
T
Siahanidou
Vangelis
V
Karalis
Eirini
E
Zervaki
Yannis
Y
Dotsikas
Yannis L
YL
Loukas
Maria
M
Theodoridou
D000998:Antiviral Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D018890:Chemoprevention; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D008297:Male; D053139:Oseltamivir / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000998:Antiviral Agents; D053139:Oseltamivir; C535162:oseltamivir carboxylate